tetracycline and Behcet-Syndrome

Behçet's disease is characterized with multifactorial etiopathogenesis and multiclinical pictures. The treatment of patients with Behçet's disease is based on the severity of illness, and the most appropriate management of Behçet's disease requires a multidisciplinary approach. Although various therapeutic modalities have been employed for Behçet's disease, treatment is far from satisfactory. Treatment of Behçet's disease includes local, systemic, or surgical therapies. Limited success has been found with colchicine, azathioprine, indomethacin, cyclophosphamide, chlorambucil, levamisole, transfer factor, fibrinolytic therapy, and systemic corticosteroid. New therapeutic approaches have been introduced for Behçet's disease using cyclosporine, thalidomide, interferon, acyclovir, high-dose corticosteroids or cyclophosphamide pulse therapy, and FK 506. We suggest that therapeutic agents should be selected after thorough evaluation of the immune state of each patient by using various tests and by determining any aggravating or provoking factors involved. In general, a combination-agent regimen is more effective than a single-agent regimen. Early diagnosis and proper treatment can inhibit or at lease slow the progress of the disease remarkably.

Topics: Adrenal Cortex Hormones; Behcet Syndrome; Cyclophosphamide; Humans; Immunosuppressive Agents; Tetracycline; Thalidomide; Zinc Sulfate

To evaluate endoscopic findings and the prevalence of H pylori in patients with Behcet's disease (BD) who have upper gastrointestinal symptoms.. The patients with BD diagnosed according to the International Study Group and followed up in the Department of Dermatology and other related departments and who had any upper gastrointestinal complaints, were included in this study. Forty-five patients with BD and 40 patients in the control group were evaluated by upper gastrointestinal endoscopy and two biopsied specimens were taken during endoscopy for H pylori. A two-week triple therapy for H pylori eradication was administered to H pylori positive patients. Two months after the treatment, the patients were evaluated by urea-breath test for eradication control.. Patients with BD had a mean age of 36.2 +/- 11.4 years (18-67 years). The mean follow-up time was 35 +/- 14 mo (16-84 mo). Aphthous or deep ulcer in esophagus, stomach and duodenum had never been confirmed by endoscopic examination. Most gastric lesions were gastric erosion (40%) and the most duodenal lesions were duodenitis (17.5%) in two groups. H pylori was positive in 33 patients (73.3%) with BD. The two-week triple eradication therapy was successful in 75% of the patients. There was no difference between the groups in respect to prevalence of H pylori (73.3% vs 75%, P > 0.05), and eradication rate (75% vs 70%, P > 0.05).. Endoscopic findings, eradication rate and prevalence of H pylori were similar in patients with BD and control group.

Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Behcet Syndrome; Biopsy; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prevalence; Pyloric Antrum; Tetracycline

Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Drugs, Generic; Female; Humans; Tetracycline

A case of incomplete mucocutaneous Behçet's disease is presented. In spite of weekly to monthly attacks of genital pain for fifteen years, this diagnostic entity had been ignored. We wish to emphasize that Behçet's disease may be the cause of otherwise unexplained genital erosions. A set of clinical criteria according to an international study group serves to establish the diagnosis. Treatment is controversial. This case has been successfully treated with systemic tetracycline for more than six months.

Topics: Adult; Behcet Syndrome; Diagnosis, Differential; Female; Humans; Tetracycline; Vagina; Vasculitis

The various forms of aphthous stomatitis and Behcet syndrome share common signs that were discussed during a conference workshop. Four markers should be considered in determining the presence of these diseases: hematologic abnormalities, HLA, antibody responses, and immune complexes.

Topics: Animals; Autoimmune Diseases; Behcet Syndrome; Folic Acid Deficiency; Humans; Immunity, Cellular; Iron Deficiencies; Levamisole; Recurrence; Stomatitis, Aphthous; Tetracycline; Vitamin B 12 Deficiency

A 46-year-old man with Behçet syndrome and a long history of recurrent bouts of colitis was studied by sigmoidoscopy, barium enema x-ray film, and colon biopsy. A nonspecific colitis characterized by shallow mucosal ulcerations and submucosal mononuclear infiltration in the absence of meaningful roentgenolographic changes was seen. A histopathological comparison was made between the oral and colonic lesions. The aphthous colitis appears, therefore, to be a colonic manifestation of Behçet syndrome, differing from typical chronic nonspecific ulcerative colitis in terms of clinical course, severity, and histologic appearance. The simultaneous occurrence of Behçet syndrome and inflammatory disease of the colon was discussed in terms of the differential diagnosis of colitis.

Topics: Adult; Behcet Syndrome; Colitis; Colitis, Ulcerative; Colon; Diagnosis, Differential; Humans; Male; Mouth Mucosa; Radiography; Tetracycline

Topics: Adenoviridae; Autoantibodies; Behcet Syndrome; Humans; Immunity, Cellular; Lymphocyte Activation; Recurrence; Steroids; Stomatitis; Stomatitis, Aphthous; Streptococcus; Tetracycline

Topics: Arthritis; Behcet Syndrome; Dentures; Esophageal Diseases; Fistula; Humans; Male; Middle Aged; Mouth Diseases; Pharyngeal Diseases; Tetracycline

Topics: Adrenal Cortex Hormones; Azathioprine; Behcet Syndrome; Drug Synergism; Humans; Male; Middle Aged; Sulfonamides; Tetracycline; Time Factors